LONDON (Alliance News) - Life sciences company Abzena PLC on Wednesday said US biotechnology company Gilead Sciences is to move the GS-5745 antibody directly into a phase 3 clinical study in gastic cancer in the third quarter of this year.
The antibody uses Abzena's Composite Human Antibody technology. It is currently under evaluation for pancreatic cancer in a phase 1b study also and a phase 2 study for its use in Crohn's disease has also been initiated.
"We are encouraged by the clinical progress that Gilead is making with GS-5745 across a range of indications," said Abzena Chief Executive John Burt.
Shares in Abzena were untraded Wednesday, having last traded at 82.70 pence.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
